EyePoint announces presentations at three upcoming meetings

EyePoint Pharmaceuticals announced that the Company will present at upcoming medical meetings and an investor conference. Presentation details are as follows: Title: The Year in Review. Dr. Duker will present interim masked safety data through October 1, 2023, in which approximately 173 patients have received EYP-1901 with a minimum of four months of follow-up post injection from the ongoing Phase 2 PAVIA and DAVIO 2 clinical trials and the completed DAVIO 1 trial. The results demonstrate the excellent safety profile of EYP-1901 with no reported drug-related ocular serious adverse events or drug-related systemic SAEs. American Academy of Ophthalmology Annual Meeting 2023. Title: Receptor Inhibition and Neuroprotection with Tyrosine Kinase Inhibitor Vorolanib for Retinal and Choroidal Diseases Dr. Avery will present preclinical data from a validated rodent retinal detachment model, which demonstrated that vorolanib, the active drug in EYP-1901, significantly reduced the severity of change in baseline visual acuity and improved contrast thresholds in mice treated with vorolanib compared with placebo, suggesting a neuroprotective effect against photoreceptor degeneration. Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference 2023. The Eyecelerator and AAO Annual Meeting presentation materials and a webcast and subsequent archived replay of the Guggenheim fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com.